Latest stories on NGNE
Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
StockTitan50 · neutralgeneral
Neurogene to Participate in Upcoming Investor Conferences
StockTitan52 · neutralproduct/pr
NGNE Reiterated by HC Wainwright & Co. -- Price Target Maintained at $65
GuruFocus55 · neutralanalyst
Neurogene presents new data on NGN-401 gene therapy at ESGCT 2026
The Fly58 · neutralproduct/pr
Neurogene Presents New Data at ESGCT Congress that Reinforce Key Differentiators of NGN-401 Gene Therapy for Rett Syndrome
StockTitan61 · neutralproduct/pr
Neurogene is a new Overweight at J.P. Morgan on Rett syndrome therapy
Seeking Alpha64 · neutralanalyst
Neurogene initiated with an Overweight at JPMorgan
The Fly63 · neutralanalyst
JPMorgan initiates Neurogene stock rating at Overweight on gene therapy potential
Investing.com Analyst Ratings64 · neutralanalyst
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
StockTitan50 · neutralgeneral
Neurogene to Participate in H.C. Wainwright 28th Annual Global Investment Conference
StockTitan55 · neutralgeneral
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
StockTitan50 · neutralgeneral
Neurogene stock price target lowered to $65 by H.C. Wainwright
Investing.com Analyst Ratings34 · bearishanalyst
Canaccord lowers Neurogene stock price target on valuation review
Investing.com Analyst Ratings42 · neutralanalyst
Neurogene GAAP EPS of -$1.05 beats by $0.37
Seeking Alpha56 · neutralearnings
Neurogene Inc. (NGNE) files 8-K
SEC 8-K50 · neutralgeneral
Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates
StockTitan28 · bearishgeneral
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
StockTitan50 · neutralgeneral
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | NGNE Stock News
StockTitan50 · neutralgeneral
Neurogene: 'Hold' EMBOLDEN Study Underway And 2nd Half 2027 Topline Data
Seeking Alpha56 · neutralanalyst
Neurogene Inc. (NGNE) files 8-K
SEC 8-K50 · neutralgeneral
Neurogene prices $125M equity offering
Seeking Alpha24 · bearishgeneral
Neurogene Inc. Announces Pricing of $125 Million Public Offering | NGNE Stock News
StockTitan24 · bearishgeneral
Neurogene Inc. (NGNE) Discusses Updated Phase 1/2 Data for NGN-401 Gene Therapy in Rett Syndrome - Slideshow
Seeking Alpha59 · neutralproduct/pr
Neurogene launches public stock offering
Seeking Alpha24 · bearishgeneral